Tesamorelin — Research Reference

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino-acid GHRH(1-44) sequence with a trans-3-hexenoic acid group added to the N-terminus. This modification increases resistance to enzymatic degradation compared to native GHRH while preserving full receptor binding activity. It is approved as Egrifta by the FDA for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy — making it one of the few GHRH analogues with a clinical approval.

Quick Reference

Parameter	Reported Value
Full name	Tesamorelin
Amino acids	44 (GHRH analogue with N-terminal modification)
Molecular weight	~5,136 Da
Half-life	~26 minutes (reported)
Common reported doses	1–2 mg per day
Administration route	Subcutaneous
Storage (lyophilized)	Refrigerator preferred; reconstitute immediately before use
Regulatory status	Approved pharmaceutical (Egrifta) for HIV-associated lipodystrophy

Overview

Tesamorelin was developed by Theratechnologies Inc. Its FDA approval for HIV-associated lipodystrophy — a condition characterised by accumulation of visceral adipose tissue linked to antiretroviral therapy — is based on robust Phase 3 clinical trial data demonstrating significant visceral fat reduction. This regulatory approval provides a clinical evidence base not available for most GHRH analogues.

Research has investigated tesamorelin for its potential role in:

Visceral fat reduction: Clinical trials in HIV-associated lipodystrophy reported approximately 15–18% reductions in visceral adipose tissue (VAT) over 26 weeks at 2 mg/day
GH and IGF-1 elevation: Tesamorelin stimulates pulsatile GH secretion from the pituitary, with downstream elevation of IGF-1 — the primary anabolic mediator of GH action
Non-alcoholic fatty liver disease (NAFLD/MASH): Research has investigated tesamorelin for potential hepatic fat reduction in HIV-positive individuals, with some trial data reporting improvements in liver fat content and liver enzyme levels
Cognitive function: A pilot randomised controlled trial investigated tesamorelin for cognitive outcomes in older adults with mild cognitive impairment, reporting improvements in verbal memory and executive function — an area of growing research interest
Body composition in ageing: Research has investigated GHRH analogues in the context of somatopause (age-related decline in GH secretion) and associated body composition changes

Tesamorelin differs from CJC-1295 in preserving the full 44-amino-acid GHRH sequence (versus a 30-amino-acid analogue for CJC-1295) and in having clinical approval data.

Reported Protocols

The following information represents commonly reported research ranges and the clinical protocol associated with the Egrifta approval. These are not medical recommendations.

Clinical Protocol (Egrifta Approved Indication)

The approved dose for HIV-associated lipodystrophy is 2 mg subcutaneously once daily, administered to the abdomen. The clinical development programme used this dose consistently across Phase 2 and Phase 3 trials.

Research Context Protocol

In research contexts outside the approved indication, commonly reported doses range from 1 mg to 2 mg per day, administered subcutaneously:

Frequency: Once-daily subcutaneous injection is the standard approach, consistent with the clinical protocol and the ~26-minute half-life (the effect on GH pulsatility persists beyond the peptide’s plasma half-life)
Duration: Clinical trials ran 26–52 weeks. Anecdotal research accounts describe cycles of 12–24 weeks, reflecting the observation that visceral fat reduction and body composition changes require sustained use
Timing: Anecdotal accounts frequently describe injection in the morning or evening in a fasted state, consistent with the approach used in clinical protocols

Egrifta Reconstitution Note

The pharmaceutical Egrifta product requires reconstitution before each use (the commercial product contains lyophilized powder and a separate diluent). It is designed for single-use reconstitution. Research compound versions vary in presentation.

Reported Effects

The following effects have been reported in clinical research and anecdotal accounts. This list reflects the research landscape, not confirmed outcomes for all individuals.

Visceral Fat Reduction

Phase 3 clinical trial data (Falutz 2007, 2010) reported statistically significant reductions in visceral adipose tissue of approximately 15–18% over 26 weeks in adults with HIV-associated lipodystrophy receiving 2 mg/day. This is the primary evidence base for tesamorelin’s fat-reducing effects and is more robust than that available for most research GHRH analogues.

IGF-1 and GH Elevation

Clinical trials consistently reported elevated IGF-1 levels in participants receiving tesamorelin — an expected pharmacological consequence of enhanced GH pulsatility. IGF-1 elevation is proposed as the mediator of downstream body composition effects.

Liver Fat Reduction

Research has investigated tesamorelin for potential reduction of hepatic fat content in HIV-positive individuals with metabolic complications. Some trial data has reported improvements in liver fat and liver enzyme levels.

Cognitive Effects

A randomised controlled pilot trial in older adults without HIV (Baker et al., 2012) reported improvements in verbal memory and executive function with tesamorelin compared to placebo. This area represents an emerging research direction beyond the approved indication.

Reported Side Effects

Reported side effects in research and anecdotal accounts include the following.

Side Effect	Frequency Reported
Injection site reactions (pain, redness, bruising)	Very common
Peripheral oedema (water retention)	Common
Arthralgia (joint discomfort)	Common
Myalgia (muscle aches)	Occasionally reported
Nausea	Occasionally reported
Paraesthesia (tingling, numbness)	Occasionally reported
Glucose metabolism effects	Reported in clinical data (GH elevates blood glucose)

Glucose and insulin resistance: Growth hormone elevation — the primary mechanism of tesamorelin — is associated with transient insulin resistance. Clinical trial data reported modest increases in fasting blood glucose and HbA1c in some participants. Individuals with pre-existing glucose dysregulation or diabetes should note this effect.

IGF-1 elevation: Sustained IGF-1 elevation at supraphysiological levels has been associated with theoretical cancer risk concerns, as IGF-1 is a growth factor. Clinical trial data has not demonstrated an increased cancer incidence, but this theoretical consideration is disclosed in the Egrifta prescribing information.

Storage & Handling

Lyophilized Powder (Unreconstituted)

Room temperature: Short-term stability reported; refrigerator strongly preferred
Refrigerator (2–8°C): Required for extended storage; protect from light
Do not freeze the dry powder
Light sensitivity: Protect from light

Reconstituted Solution

Use promptly: Unlike many peptides reconstituted with BAC water for multi-day use, the pharmaceutical Egrifta is designed for single-use reconstitution. Research compound versions reconstituted with BAC water may be stored refrigerated for 4–6 weeks, but stability data specific to tesamorelin in this context is limited
Do not freeze a reconstituted solution
Discard if the solution becomes cloudy, discoloured, or shows particulate matter

Reconstitution

Follow product-specific instructions; for research compound forms, add bacteriostatic water slowly along the inside wall of the vial and swirl gently. See the Reconstitution Guide for step-by-step instructions.

Frequently Asked Questions

How does tesamorelin compare to CJC-1295? Tesamorelin is the full 44-amino-acid GHRH sequence with N-terminal stabilisation; CJC-1295 is a 30-amino-acid GHRH analogue (Mod GRF 1-29 sequence, residues 1-29 of GHRH). Tesamorelin has the advantage of clinical trial data and FDA approval supporting its efficacy for visceral fat reduction. CJC-1295 (without DAC / Mod GRF 1-29) is more widely available in research compound form and is more commonly described in combination with ipamorelin in anecdotal research accounts.

Is the approved dose of 2 mg the same in research contexts? The FDA-approved dose is 2 mg/day for HIV-associated lipodystrophy. Research accounts outside this indication describe the same dose range (1–2 mg/day), reflecting the clinical data. Some anecdotal researchers describe lower doses (1 mg/day) for longer cycles.

Does tesamorelin require cycling? Clinical trial data on tesamorelin used continuous administration for up to 52 weeks. Anecdotal research accounts vary — some describe cycles of 12–24 weeks followed by breaks, others describe extended continuous use. The long-term effects of extended continuous GH stimulation in healthy individuals have not been studied.

Is tesamorelin the same as sermorelin? No. Sermorelin is an unmodified GHRH(1-29) fragment with a half-life of approximately 10–20 minutes and is approved for different indications in some countries. Tesamorelin is the full GHRH(1-44) sequence with an N-terminal modification and a somewhat longer half-life.

Goals: Muscle Growth · Fat Loss · Performance

Class: GHRH Analogues

References & Further Reading

Falutz J, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359–2370. PubMed →
Stanley TL, Grinspoon SK. (2015). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV-infected patients with abdominal fat accumulation. AIDS, 29(18), 2397–2408. PubMed →
Baker LD, et al. (2012). Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Archives of Neurology, 69(11), 1420–1429. PubMed →